Status: Recruiting
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
The T-RRex study evaluates the efficacy of WU-CART-007 for patients with Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL) and to WU-CART-007 as a therapy to induce complete Minimum Residual Disease (MRD) negative response
Participants needed: 125
Trial details
Phase: Phase 2Age: 1+Biological sex: AllType: InterventionalSponsor: Wugen, Inc.Updated: May 12, 2026Locations: 15
Eligibility criteria
Disease Criteria: Evidence of T-ALL or T-LBL, as defined by World Health Organiz... [+2]
Prior treatment with any anti-CD7 therapy. [+2]